Novelty Nobility, a clinical-stage South Korean biotech company, has expanded its manufacturing agreement with AGC Biologics to advance its bispecific antibody drug candidate NN4101 through process development and GMP manufacturing at AGC Biologics' Chiba, Japan facility. The collaboration follows successful cell line development completed in Copenhagen, Denmark. NN4101 is a first-in-class bispecific antibody targeting neovascular retinal diseases, combining a fully human anti-c-Kit monoclonal antibody with a VEGF trap. The partnership leverages AGC Biologics' global network across the US, Europe and Asia. AGC Biologics is expanding its Japanese operations with a new state-of-the-art facility in Yokohama, designed to offer large-scale GMP manufacturing using single-use bioreactor technology to meet growing regional and global demand.

Novelty Nobility taps AGC Biologics to further develop bispecific drug candidate. AGC Biologics, Inc. Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in bioprocessing and AGC Biologics' expanding global network CHIBA, Japan, May 04, 2026 (GLOBE NEWSWIRE) - Novelty Nobility, a clinical-stage biotech company based in South Korea, expanded its manufacturing agreement with AGC Biologics, your friendly CDMO expert, to advance their bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics' facility in Chiba, Japan. This second partnership, continued from the last year, underscores the successful track record and deep expertise AGC Biologics provides for developing complex biologics. The project leverages AGC Biologics' global network, having successfully completed cell line development in Copenhagen, Denmark. The program is now on track for a seamless tech transfer to the Chiba site for the next critical manufacturing stages. "AGC Biologics has proven to be an ideal manufacturing partner for advancing our most complex programs. Their seamless global network - from cell line development to GMP manufacturing - gives us the confidence to move NN4101 forward with speed and precision." said Sang Gyu Park, CEO of Novelty Nobility. "We believe this bispecific antibody has the potential to offer a truly differentiated treatment option for patients with neovascular retinal diseases." Novelty Nobility's bispecific antibody drug candidate NN4101 is a first-in-class bispecific antibody intended for the treatment of neovascular retinal diseases. It uniquely connects a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap. "Our continued partnership with Novelty Nobility is a testament to the trust and confidence customers have in our technical expertise and our global network's capabilities," said Tadashi Murano, President of the AGC Life Science Company. "Our mammalian expression teams are adept at handling complex proteins, and we are a world leader in applying flexible, single-use bioreactor technology. We are proud to support Novelty Nobility as they advance this innovative candidate toward the clinic." The project highlights the power of AGC Biologics' integrated global facility network, offering customers a seamless experience by combining world-class expertise with a strong regional presence. To further support growing demand in the region and globally, AGC Biologics is expanding its footprint in Japan with a new state-of-the-art facility in Yokohama. The Yokohama site is designed to utilize the latest single-use bioreactor technology to offer large-scale GMP manufacturing, making it one of the most advanced facilities of its kind in Japan. "When clients work with us, they tap into our entire global network which brings teams together for a seamless experience," noted Susumu Zen-in, Senior Vice President and General Manager of AGC Biologics' Chiba site. "This approach is creating wins for our partners and for AGC Biologics throughout the APAC region. The upcoming capacity at our new Yokohama site will only strengthen our ability to meet the global demand for vital biopharmaceuticals." About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as Connectweb work side-by-side with its clients and partners, to provide friendly and expert services. Connectweb provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Its global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. About Novelty Nobility Novelty Nobility is a clinical-stage biotech company driven by a mission to maximize the potential of therapeutic antibodies. The company is dedicated to developing next-generation treatments for immunology and inflammatory diseases. Leveraging its proprietary fully human antibody discovery platform, PREXISE(R)-D, together with deep expertise in protein engineering, Novelty Nobility is advancing a diverse pipeline of monoclonal antibodies (mAb), bispecific antibodies (bsAb), and antibody-drug conjugates (ADC) - modalities where scientific novelty translates into meaningful benefits for patients.

Autolus (NASDAQ: AUTL) signs 10-year AGC Biologics lentiviral supply pact. Rhea-AI filing summary. Autolus Therapeutics plc filed a prospectus supplement covering the resale by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs), including 3,265,306 ADSs issuable upon exercise of outstanding warrants. The ADSs trade on Nasdaq under the symbol AUTL, and the closing price on January 23, 2026 was $1.46 per ADS. The supplement also incorporates an 8-K describing a new 10-year Master Supply Agreement between Autolus Limited and AGC Biologics S.p.A for lentiviral vector, a critical raw material for the company's CAR-T products, including AUCATZYL and clinical trial products. Autolus Limited committed to purchase a minimum of 14 batches of lentiviral vector in the first two calendar years and a minimum value of EUR 25 million of products and services over the subsequent five-year period, under a non-exclusive arrangement that gives AGC a first right to negotiate new manufacturing activities for the obe-cel product. Insights. Autolus locks in long-term viral vector supply with minimum purchase commitments. Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics, entered a 10-year Master Supply Agreement with AGC Biologics S.p.A for lentiviral vector, which is described as critical for manufacturing the company's CAR-T products, including AUCATZYL and clinical trial materials. The pact is non-exclusive but establishes the general terms for products and services via individual work orders. The company has committed to buy a minimum of 14 batches of lentiviral vector in the first two calendar years and at least EUR 25 million of products and services over the following five-year period. These minimums help secure supply continuity but also create multi-year purchase obligations whose scale, relative to Autolus's overall spending, is not detailed in the excerpt. The agreement runs for ten years and can be terminated for default by either party or by the company on notice subject to certain fees, while AGC receives a first right to negotiate new manufacturing activities for the obe-cel product. Future filings, such as the Form 10-Q for the quarter ending March 31, 2026, may provide the filed agreement text and more granular financial impact. Faq. The prospectus supplement relates to the resale from time to time by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs), representing the same number of ordinary shares. This includes 51,318,944 ADSs representing existing ordinary shares and up to 3,265,306 ADSs issuable upon exercise of outstanding warrants. Is Autolus Therapeutics itself selling ADSs in this AUTL filing? The document states that the Prospectus and this supplement relate to the resale of ADSs by identified selling securityholders. It does not describe Autolus Therapeutics plc as the seller of these securities, focusing instead on holders who may sell from time to time under the registration. What new agreement did Autolus disclose with AGC Biologics in this filing? Autolus Limited entered into a Master Supply Agreement with AGC Biologics S.p.A on January 21, 2026 for the manufacture and supply of lentiviral vector. The agreement sets out terms under which AGC will provide products and services to support Autolus's CAR-T manufacturing operations. How long is the AGC Biologics supply agreement with Autolus and can it be terminated? The Master Supply Agreement runs for a fixed term of ten years. It may be terminated by either party for default, and it may be terminated by the company upon written notice, in which case the company must pay certain fees as specified in the agreement. What minimum purchase commitments does Autolus have under the AGC Master Supply Agreement? Under the agreement and initial statement of work, Autolus Limited committed to purchase a minimum of 14 batches of lentiviral vector during the first two calendar years of the term and to purchase a minimum value of EUR 25 million of products and services during the subsequent five-year period. Why is the AGC lentiviral vector supply important for Autolus Therapeutics (AUTL)? The filing describes lentiviral vector supplied by AGC as a critical raw material for manufacturing the company's CAR-T products. Autolus Limited is noted as the sole manufacturer of all CAR-T products supplied by Autolus's operational companies globally, including commercial AUCATZYL and clinical trial products. What special rights does AGC Biologics receive regarding Autolus's obe-cel product? The agreement gives AGC Biologics the first right to negotiate with Autolus Limited for new manufacturing activities related to the company's obecabtagene autoleucel (obe-cel) product, as described in the filing.